These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33556418)

  • 21. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs.
    Han J; Shin HC; Kim JC; Kim B
    Food Chem Toxicol; 2004 Mar; 42(3):373-80. PubMed ID: 14871579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sub-acute toxicological study of artemisinin-piperaquine tablets in rhesus monkeys.
    Li X; Xu Z; Yuan Y; Ru L; Yuan Z; Zhang S; Wang Q; Song J; Xu Q
    Regul Toxicol Pharmacol; 2019 Dec; 109():104486. PubMed ID: 31580888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
    Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
    Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
    Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E
    Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.
    Bernard-Gauthier V; Schirrmacher R
    Expert Opin Ther Pat; 2016; 26(2):291-5. PubMed ID: 26561352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
    Mausumee G; Frank S; Shawn C; Dara H; Zhao Y; Soleil PM; Sanderson TP; Michael G; Marc D
    Int J Toxicol; 2014 May; 33(3):204-218. PubMed ID: 24846376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
    Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
    J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated injection of KMRC011, a medical countermeasure for radiation, can cause adverse health effects in cynomolgus monkeys.
    Lee HS; Park YJ; Cho DW; Han SC; Jun SY; Jung GM; Lee WJ; Choi CM; Park EJ; Pak SI
    J Appl Toxicol; 2019 Feb; 39(2):294-304. PubMed ID: 30277593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
    Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP; Loong HH; Huang PH; Jones RL
    Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative toxicokinetics of MMB4 DMS in rats, rabbits, dogs, and monkeys following single and repeated intramuscular administration.
    Hong SP; Gibbs ST; Kobs DJ; Hawk MA; Croutch CR; Osheroff MR; Johnson JD; Burback BL
    Int J Toxicol; 2013; 32(4 Suppl):38S-48S. PubMed ID: 23929448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs.
    Han J; Kim JC; Chung MK; Kim B; Choi DR
    Biol Pharm Bull; 2003 Jun; 26(6):832-9. PubMed ID: 12808295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).
    Prahalada S; Tarantal AF; Harris GS; Ellsworth KP; Clarke AP; Skiles GL; MacKenzie KI; Kruk LF; Ablin DS; Cukierski MA; Peter CP; vanZwieten MJ; Hendrickx AG
    Teratology; 1997 Feb; 55(2):119-31. PubMed ID: 9143092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys.
    Chen Y; Dale Thurman J; Kinter LB; Bialecki R; Eric McDuffie J
    Toxicol Appl Pharmacol; 2017 Dec; 336():66-74. PubMed ID: 29051111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute toxicity, 28-day repeated-dose toxicity and toxicokinetic study of timosaponin BII in rats.
    Lin N; Liu B; Zhang J; Long Y; Dong G; Jin H; Ma B
    Regul Toxicol Pharmacol; 2017 Nov; 90():244-257. PubMed ID: 28947379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeat oral dose toxicity studies of melamine in rats and monkeys.
    Early RJ; Yu H; Mu XP; Xu H; Guo L; Kong Q; Zhou J; He B; Yang X; Huang H; Hu E; Jiang Y
    Arch Toxicol; 2013 Mar; 87(3):517-27. PubMed ID: 23052191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.